Controlled trial of RSV, herbs or placebo as adjuvants to complete resection of squamous cell lung cancer.
152 completely resected patients with high or intermediate differentiated squamous cell lung cancer were randomized to receive 6 months adjuvant therapy with RSV (1, 2-diphenyl-alpha beta-diketone) herbs or placebo. No significant differences were observed in duration of survival or relapse rates between the three groups.